Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) had its price target upped by equities research analysts at Robert W. Baird from $252.00 to $280.00 in a research note issued to investors on Tuesday,Benzinga reports. Finally, Canaccord Genuity Group began coverage on Jazz Pharmaceuticals in a report on Thursday, July 16th. Get Jazz Pharmaceuticals alerts:View Our Latest Research Report on JAZZJazz Pharmaceuticals Trading Down 0.5%NASDAQ:JAZZ opened at $251.58 on Tuesday. Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last posted its earnings results on Monday, August 3rd. Read MoreReceive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.